Objective The Pharmaceutical sector is a mainstay of the European economy. However, changing patterns of drug discovery and competition has greatly enhanced the need for a SME sector to produce new drug leads and targets to feed big Pharma pipelines. This application addresses the need by coalescing partners involved in the identification/validation of new targets and in drug design, synthesis and discovery. The focus is on type 2 diabetes, obesity and immune diseases which cause serious disability and reduced life expectancy globally. Dualsystems and NUIM will be involved in the identification/validation of protein interactions involved in the pathway linking retinol binding protein and insulin, through which the former, when elevated in obesity, inhibits responses to the latter thereby contributing to type 2 diabetes. A second project will identify the protein machinery involved in the failure of otherwise active natural mutants of the MC4 receptor to traffic to the cell surface. This failure produces 6-7% of cases of gross genetic obesity. The third project will identify native protein ligands for a new family of G-protein coupled receptors (LNB-GPCRs), deeply implicated in immune-related diseases and cancer. The transfer of knowledge (TOK) involve development and use of yeast 2-hybrid systems to identify putative interactors and of rapid in vitro systems for interacting protein validation. A new yeast-based biosensor system will be advanced from “proof of concept” to the development stage. AFChemPharm focuses on new systems of chemical synthesis. They will work with NUIM on protein modelling, drug design, in silico screening and chemical synthesis to produce selected panels of compounds to screen for “hits” and to optimise into “leads. The TOK and skills acquisition will involve state of the art computational approaches in modelling, drug design and screening, together with their amalgamation with new synthetic processes to tailor/refine design and synthesis. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicinemedicinal chemistrynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineendocrinologydiabetesmedical and health scienceshealth sciencesnutritionobesity Programme(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Topic(s) FP7-PEOPLE-2009-IAPP - Marie Curie Action: "Industry-Academia Partnerships and Pathways" Call for proposal FP7-PEOPLE-2009-IAPP See other projects for this call Funding Scheme MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP) Coordinator NATIONAL UNIVERSITY OF IRELAND MAYNOOTH EU contribution € 159 569,00 Address CO KILDARE W23 Maynooth Ireland See on map Region Ireland Eastern and Midland Mid-East Activity type Higher or Secondary Education Establishments Administrative Contact John Findlay (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (2) Sort alphabetically Sort by EU Contribution Expand all Collapse all Dualsystems Biotech AG Switzerland EU contribution € 171 580,00 Address Grabenstrasse 11a 8952 Zurich-Schlieren See on map Region Schweiz/Suisse/Svizzera Zürich Zürich Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Daniel Auerbach (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data AF ChemPharm Ltd United Kingdom EU contribution € 312 338,00 Address Bailey Street - Bailey House 5-11 S14EH Sheffield See on map Region Yorkshire and the Humber South Yorkshire Sheffield Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Asad Fallah (Dr.) Links Contact the organisation Opens in new window Total cost No data
